Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study
Allergy · 2026
DOI: 10.1111/all.16640 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2026. Verfasst von Janice A Layhadi und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Seasonal, Poaceae, Immunity, Humoral, Allergens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergy Therapeutics.
Abstract (Originalsprache)
Background
A short‐course pre‐seasonal subcutaneous injection of PQ Grass is clinically effective for the treatment of allergic rhinitis, though its mechanism remains unclear. The aim of the study was to interrogate immunological mechanisms induced by PQ Grass conventional and extended regimens.
Methods
A RDBPC exploratory field study involving participants that either received injections of PQ Grass with a cumulative dose of 27,600 SU conventional (six once weekly injections) or extended regimen (three once weekly injections followed by three once monthly injections) or placebo containing microcrystalline tyrosine (MCT) (placebo + MCT) or saline (placebo) was performed. Humoral, cellular, and molecular responses were assessed at baseline (V1), end of treatment, prior to grass pollen season (V12) and end of pollen season (V15). Immunoglobulin analyses and cellular/gene microarray analyses were performed in the sub‐study cohort consisting of PQ Grass Conventional ( n = 25 and n = 10, respectively), PQ Grass Extended ( n = 26 and n = 10, respectively), Placebo with MCT ( n = 13 and n = 5, respectively), and Placebo (saline; n = 12 and n = 5, respectively).
Results
Both PQ Grass regimens, conventional and extended, were associated with improvement in total combined scores (TCS) with a relative difference of −35.0% ( p = 0.03) and −40.8% ( p = 0.01) against placebo with MCT, respectively. Both PQ Grass treatment regimens were associated with increases in the sIgG 4 /sIgE ratio (all, p < 0.05) and induction of IgA 1 (all, p < 0.05) and IgA 2 (all, p < 0.01) compared to placebo groups. Nasal fluid ( p < 0.01) and serum ( p < 0.05) blocking antibodies are functional and have the capacity to inhibit allergen‐IgE complex formation and binding to B cells in the PQ Grass groups. In vitro cellular and microarray gene analyses demonstrated that the extended PQ Grass regimen was more proficient in modulating the immune response towards a tolerogenic milieu by dampening pro‐inflammatory type 2 immune response and the associated cytokines ( p < 0.05), immune deviation towards a Th1 response ( p < 0.05), and induction of FOXP3 + Treg cells ( p < 0.05).
Conclusions
For the first time, we highlight differential mechanisms of tolerance induction by PQ Grass, with the extended regimen being superior in modulating T cell compartments. Trail Registration Trial number: PQGrass309, EudraCT number: 2020‐000408‐13, Clinicaltrials.gov identifier: NCT04687059, and NCT05540717
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute, Imperial College London, London, UK.
- Allergy Therapeutics PLC, Worthing, UK.
- Bencard Allergie GmbH, Munich, Germany.
ORCID-Profile: Janice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, Elizabeth Palmer, Lily Y D Wu, Sean T Keane, William T Fulton, Prista Hikmawati, Xun Meng, Kemi Oluwayi, Katarzyna Lis, Oliver Armfield, Murray A Skinner, Matthew D Heath, Matthias F Kramer, Mohamed H Shamji
Förderung
- Allergy Therapeutics
Zitieren
APA
Layhadi, J. A., Starchenka, S., De Kam, P. J., Palmer, E., Wu, L. Y. D., Keane, S. T., Fulton, W. T., Hikmawati, P., Meng, X., Filipaviciute, P., Cutrina Pons, A., Oluwayi, K., Lis, K., Armfield, O., Skinner, M. A., Heath, M. D., Hewings, S. J., Kramer, M. F., & Shamji, M. H. (2026). Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. https://doi.org/10.1111/all.16640
Vancouver
Layhadi JA, Starchenka S, De Kam PJ, Palmer E, Wu LYD, Keane ST, et al. Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. 2026. doi:10.1111/all.16640
BibTeX
@article{Layhadi2026,
author = {Layhadi, Janice A and Starchenka, Sviatlana and De Kam, Pieter-Jan and Palmer, Elizabeth and Wu, Lily Y D and Keane, Sean T and Fulton, William T and Hikmawati, Prista and Meng, Xun and Filipaviciute, Paulina and Cutrina Pons, Anna and Oluwayi, Kemi and Lis, Katarzyna and Armfield, Oliver and Skinner, Murray A and Heath, Matthew D and Hewings, Simon J and Kramer, Matthias F and Shamji, Mohamed H},
title = {Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.16640}
}
EUVIMED